about
Fast relapse and high drop out rate of 48 weeks daily interferon monotherapy in HIV-infected patients with chronic hepatitis C.Triple therapy with first-generation protease inhibitors for patients with genotype 1 chronic hepatitis C: recommendations of the Italian association for the study of the liver (AISF)Spatial and temporal dynamics of hepatitis B virus D genotype in Europe and the Mediterranean BasinGenetic variation in IL28B and treatment-induced clearance of hepatitis C virus in HIV-positive patients with acute and chronic hepatitis C.Forecast model for the evaluation of economic resources employed in the health care of patients with HIV infection.Natural history of chronic hepatitis B in co-infected patients.Hepatotoxicity and antiretroviral therapy with protease inhibitors: A review.Prophylaxis and treatment of hepatitis B in immunocompromised patients.Naturally occurring resistance mutations to inhibitors of HCV NS5A region and NS5B polymerase in DAA treatment-naïve patients.Forthcoming challenges in the management of direct-acting antiviral agents (DAAs) for hepatitis C.Treatment of chronic hepatitis B: update of the recommendations from the 2007 Italian Workshop.Recommendations for the management of mixed cryoglobulinemia syndrome in hepatitis C virus-infected patients.Hepatocellular carcinoma in HIV hepatitis C virus.Comparison of peginterferon pharmacokinetic and pharmacodynamic profiles.Hepatitis B in immunosuppressed cancer patients: pathogenesis, incidence and prophylaxis.Management of infections in cirrhotic patients: report of a consensus conference.Management of infections pre- and post-liver transplantation: report of an AISF consensus conference.Recommendations for the management of acute hepatitis B: position paper of the Italian Society for the Study of Infectious and Tropical Diseases (SIMIT).Recommendations for screening, monitoring, prevention, prophylaxis and therapy of hepatitis B virus reactivation in patients with haematologic malignancies and patients who underwent haematologic stem cell transplantation-a position paper.Beyond the gut bacterial microbiota: The gut virome.Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study.Emerging biological agents for hepatitis C.Interferon-free antiviral treatment in B-cell lymphoproliferative disorders associated with hepatitis C virus infection.Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi.Coarse vs. fine needle aspiration biopsy for the assessment of diffuse liver disease from hepatitis C virus-related chronic hepatitis.Correlation between FIB4, liver stiffness and metabolic parameters in patients with HIV and hepatitis C virus co-infection.OPERA: use of pegylated interferon plus ribavirin for treating HCV-HIV coinfection in interferon-naive patients.Ultrasound in the diagnosis of gallbladder ascariasis.Consensus conference on TIPS management: Techniques, indications, contraindications.Treatment of patients with chronic hepatitis C infection in Lombardia: a report by the Lombardia Hepatitis Network.Antibiotic stewardship and empirical antibiotic treatment: How can they get along?Cutaneous septic emboli from Candida glabrata in a haematological patient.Impact of HBV and S. mansoni on portal pressure: Synergy or innocent bystanders?Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir Combination Treatment in Patients with HIV/HCV Co-Infection: Results of an Italian Compassionate Use Program.Direct-acting antivirals during or after immunochemotherapy in hepatitis C virus-positive diffuse large B-cell lymphomas.Effect of the interleukin-6 C174G gene polymorphism on treatment of acute and chronic hepatitis C in human immunodeficiency virus coinfected patients.Dissociation of serum and liver hepatitis C virus RNA levels in patients coinfected with human immunodeficiency virus and treated with antiretroviral drugs.Epidemiological characteristics of bloodstream infections in patients with different degrees of liver disease.Liver fibrosis, microbial translocation and immune activation markers in HIV and HCV infections and in HIV/HCV co-infection.OPERA: responses to peginterferon and ribavirin therapy in a subgroup of interferon-naïve patients with HIV/HCV genotype 2/3 co-infection in Italy.
P50
Q24804388-F839FA9C-A6BD-402D-BD07-F2F0A14A30B0Q26865724-8D9118DC-C002-41FD-BA08-40579CB17888Q28483949-78A43EE4-E96A-4252-84A7-4C02FDE2999AQ34772812-92B5FB57-E0D3-4B92-97C3-91DC83C67975Q36062007-0F249D23-B693-4B2C-80F0-737431861214Q36336123-CF7E107B-14AA-41EE-94C4-DCCE6ACF958FQ36456458-6A8DF92F-289F-4C71-9A72-628C1C453AFAQ36768889-E3DA9ACD-5578-43DE-9F00-5F04C99ACBBEQ37426527-BFC828B2-2646-46A3-95ED-36FEED381AD8Q37803467-6A098FD7-D6A9-4CE6-AF0E-E6C71EC5E357Q37833228-1573979E-8D81-4060-8F51-BFA72C94ABADQ37838047-250BF039-1D00-4ED0-9D36-46A9188CD123Q37936196-8978A444-52AE-4811-AC63-557783C21BB4Q37974697-661F422D-82D7-4BC3-8C52-6B26C14A4D05Q38073460-2A2312DC-EDEF-4781-92DA-9118B75078A3Q38135971-7595D9C6-D5D4-4CD6-A543-DCF21BD5178EQ38175238-0EE7A3AB-2184-4313-B38F-EBFCB0F24641Q38226627-42FF1712-A4D2-48CC-B4BA-A74D018B320FQ38664059-FF2A4B29-626D-41C8-877A-36D9D2629B49Q38751639-72D8B928-0984-4A1A-A076-1DFEBEE88CB1Q38789871-00F041F5-E495-4F64-96FA-2EC26F40C65AQ38820156-B013B0C6-4025-4AF4-9B0C-E11B448B4EF1Q38878808-878FF3CF-C554-4175-B923-E63AA87616C9Q38878814-8F35ED5A-8B4F-4DA0-B2DA-337DDD22A45AQ38924073-4BA4D05D-2542-473F-8D4F-4DD1359AFB0AQ38924167-F337E7D6-0E2F-4570-9935-9AF401C9DC2BQ38932602-E3008190-7EBB-4B0F-9861-D863AFD27E2EQ39004361-9580ACC5-A2D0-492E-AD48-9ECE7134EC4FQ39019004-390EAC88-8721-487D-81B5-174AFD5AFC0AQ39022907-2206232D-6F9A-4454-B712-246DDFA5B3E0Q39142720-5B55DF21-ACE9-4800-9949-0DABF185CD4BQ39187893-543B0979-3475-46CC-88E9-25B9BDC76FE1Q39187897-6DB432C4-6428-44AD-BC98-18B143E9C387Q39222831-F645D229-7F57-46D3-B05F-8873333D46D3Q39246289-45A719DF-BC77-4FA4-AC00-10ED5F36E57FQ40099630-A1818012-DF5B-434A-B0DD-1A92BBC48BC9Q41040128-ED951EA8-07F1-42FC-A5A3-DE6D05B59702Q41229223-EE04DCAA-56A0-490B-8E8A-BEA20C99B2BFQ41579087-FE9CF243-7AD1-43DC-B295-2C52086B7DDDQ42205137-5701E406-5819-4247-BDB2-496F3FDAB37E
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Raffaele Bruno
@ast
Raffaele Bruno
@en
Raffaele Bruno
@es
Raffaele Bruno
@nl
Raffaele Bruno
@sl
type
label
Raffaele Bruno
@ast
Raffaele Bruno
@en
Raffaele Bruno
@es
Raffaele Bruno
@nl
Raffaele Bruno
@sl
prefLabel
Raffaele Bruno
@ast
Raffaele Bruno
@en
Raffaele Bruno
@es
Raffaele Bruno
@nl
Raffaele Bruno
@sl
P106
P1153
7101907548
P1960
MYGcyBoAAAAJ
P21
P31
P496
0000-0002-0235-9207